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Abstract Initiation factor (eIF) 4G plays a key role in the
regulation of translation, acting as a bridge between eIF4E and
eIF3, to allow an mRNA molecule to associate with the 40S
ribosomal subunit. In this study, we show that activation of the
Fas/CD95 receptor complex in Jurkat cells induces the
degradation of eIF4G, the inhibition of total protein synthesis
and cell death. These responses were prevented by the caspase
inhibitors, zVAD.FMK and zDEVD.FMK. We also show that,
in contrast to Saccharomyces cerevisiae, although rapamycin
caused a modest inhibition of protein synthesis it did not induce
apoptosis or the cleavage of eIF4G. Studies with the specific
inhibitor, SB203580, have shown that signalling through the p38
MAP kinase pathway is not required for either the Fas/CD95-
induced cleavage of eIF4G or cell death. These data suggest that
the cleavage of eIF4G and the inhibition of translation play an
integral role in Fas/CD95-induced cell death in Jurkat cells.
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1. Introduction
Apoptosis, a major form of cell death characterised by a
series of distinct morphological and biochemical changes [1],
is an important process in a wide variety of biological systems
[2], with inappropriate activation implicated in human disease
[3]. The regulation of this process has been proposed to be
mediated via a ¢ne balance between the activation of protein
synthesis-independent cytotoxic mechanisms and maintenance
of protein synthesis-dependent protective e¡ects [1,2,4].
Fas (Apo-1/CD95) encodes a transmembrane receptor be-
longing to the tumour necrosis factor (TNF) receptor family.
Interaction of the receptor with its cognate ligand or cross-
linking with anti-Fas IgM has been employed as a model
system for apoptosis, as occupation of this receptor results
in rapid programmed cell death in Jurkat cells [5,6]. The es-
sential signalling events coupling Fas/CD95 receptor to apop-
tosis have been studied intensively. It has been shown that the
intracellular domain of Fas/CD95 contains a highly conserved
‘death domain’, which is required for the induction of apop-
tosis [1,2,7]. Stimulation of Fas/CD95 results in aggregation
of its death domains, leading to the recruitment of at least two
key signalling proteins that together with the receptor, form
the death-inducing signalling complex (DISC) [2,8]. FADD/
MORT-1, an adaptor protein [9,10], couples via its C-terminal
death domain to the aggregated Fas/CD95 receptor and re-
cruits caspase 8 (FLICE/MACHK1/Mch5), a cysteine pro-
tease, through its N-terminal death e¡ector domain to the
DISC [11,12]. Recruitment of caspase 8 to the Fas/CD95
DISC results in its autocatalytic cleavage at internal Asp res-
idues, with the release of active subunits (p18 and p10) into
the cytosol [1,2,13]. In Jurkat cells, the inhibition of caspase 8
activity is su⁄cient to prevent anti-Fas IgM-induced apopto-
sis [14^17]. Downstream of the DISC, the Fas/CD95 signal-
ling pathway has been shown to involve additional caspases
(such as caspases 1, 3, 6^10), loss of mitochondrial integrity,
the release of cytochrome c and activation of caspase 9 (and
subsequently caspase 3) via its interaction with Apaf-1 (re-
viewed in [2]). Caspase 3 is believed to play the role of the
main executioner downstream in the apoptotic pathways as it
is normally activated in cells by a variety of death stimuli
[1,2], although it may not be required for all of the morpho-
logical and biochemical changes observed during this process
[18].
The role of the mitogen-activated protein kinase (MAPKs)
signalling pathways in apoptosis is more controversial.
Although activation of the ERK MAPK has been generally
associated with cell survival [19], the stress-activated MAPKs,
such as p38 MAPK and JNK [20^22], have been implicated as
possible mediators of the apoptotic process [23,24] as well as
regulating cell survival in response to TNFK [25]. Fas/CD95
receptor activation has been demonstrated to increase the ac-
tivity of p38 MAPK and JNK, in a caspase-dependent man-
ner, events which can be temporally correlated with the onset
of apoptosis [26].
Central to the process of apoptosis is the ¢nding that cas-
pase-dependent cleavage of target proteins can lead to their
inactivation (e.g. poly(ADP-ribose) polymerase (PARP), lam-
in, focal adhesion kinase (FAK)) or in some cases to their
activation (e.g. MEKK1, p21-activated kinase 2 (PAK2), pro-
tein kinase C-N, phosphatase 2A and gelsolin ([1,2,27] and
references therein). Recently, Widmann et al. have catalogued
the caspase-dependent cleavage of signalling proteins during
apoptosis and shown that cleavage of Raf-1 and Akt-1 inhib-
its their kinase activity [27]. This has been proposed to lead to
the inhibition of cell survival pathways [28,29], in part, by
preventing the ability of Akt-1 to phosphorylate and inacti-
vate BAD, a pro-apoptotic member of the Bcl family of pro-
teins [1,2]. In other physiological systems, inhibition of signal-
ling via the Akt-1 pathway has been associated with decreased
phosphorylation of ribosomal protein S6 and initiation factor
(eIF) 4E binding protein 1 (4E-BP1) (reviewed in [30]); this
results in a decrease in the translation of a class of mRNAs
containing a 5P polypyrimidine tract [31], and the sequestra-
tion of eIF4E from eIF4G producing a general inhibition of
translation, respectively [30,32].
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Previously, we have shown that starvation of BJAB cells for
serum results in decreased rates of translation, the induction
of apoptosis and the cleavage of eIF4G [33]. We now show
that activation of the Fas/CD95 receptor by anti-Fas IgM
results in an inhibition of total protein synthesis in Jurkat
cells. In addition, Fas/CD95 signalling impinges directly on
the translational apparatus by mediating the cleavage of
eIF4G, which is temporally correlated with the inhibition of
protein synthesis. The degradation of eIF4G is dependent
upon caspase 3 activity but does not require signalling
through the p38 MAPK pathway. These data suggest that
the cleavage of eIF4G and the inhibition of translation play
an integral role in cell death following activation of the Fas/
CD95 signalling pathway in Jurkat cells.
2. Materials and methods
2.1. Chemicals and biochemicals
Materials for tissue culture were from Gibco Life Technologies,
Immobilon PVDF was from Millipore, anti-Fas IgM (clone CH-11)
was from TCS Biologicals, zVAD.FMK and SB203580 were from
Alexis Corporation, zDEVD.FMK was from Calbiochem, m7GTP-
Sepharose was from Pharmacia-LKB and all other chemicals were
from Sigma. Rabbit antisera to eIF4G (raised against the C-terminal
fragment expressed in bacteria) and eIF4E (raised against a C-termi-
nal peptide) were as described previously [33,34], antiserum to PARP
was from Boehringer Mannheim and antiserum speci¢c for p38 and
phospho-p38 were from New England Biolabs. Rapamycin was a kind
gift from Dr. J. Kay (Sussex, UK).
2.2. Tissue culture
Human Jurkat T cells were grown in RPMI 1640 with Glutamax
supplemented with 10% foetal calf serum (FCS) as described previ-
ously [34]. Cell cultures, in the mid-log phase of growth, were incu-
bated for 1 h with vehicle alone, zVAD.FMK, zDEVD.FMK or
SB203580, as described in individual ¢gure legends, prior to stimula-
tion.
2.3. Preparation of cell extracts
Following treatment, cells were isolated by centrifugation in a
cooled microfuge, the medium removed and cells resuspended in
500 Wl ice cold PBS supplemented with 40 mM L-glycerophosphate
and 2 mM benzamidine. Following a wash in the same bu¡er, cells
were resuspended and lysed by vortexing in 0.2 ml (per 10 ml of
original culture) bu¡er A (50 mM MOPS-KOH, pH 7.4, 2.5 mM
EGTA, 1 mM EDTA, 40 mM L-glycerophosphate, 1 WM microcystin,
120 mM NaCl, 7 mM 2-mercaptoethanol, 2 mM benzamidine, 1 mM
phenylmethylsulphonyl £uoride (PMSF), 0.1 mM GTP, 2 mM
Na3VO4, 1% (by vol.) of each of Nonidet P40 and Triton X-100).
Cell debris was removed by centrifugation in a microfuge for 5 min at
4‡C and the resultant supernatant was frozen in liquid N2.
2.4. Polyacrylamide gel electrophoresis (SDS-PAGE), vertical slab
iso-electric focusing (VS.IEF) and immunoblotting
One-dimensional polyacrylamide gels and vertical slab iso-electric
focusing gels were run as described [34]. Proteins transferred to PVDF
and eIFE, eIF4G, PARP, p38 and phosphorylated p38 MAPKs were
detected with speci¢c rabbit anti-peptide antisera as described in the
individual ¢gure legends.
2.5. m7 GTP-Sepharose chromatography
For the isolation of eIF4E, cell extracts of equal protein concen-
tration were subjected to m7GTP-Sepharose chromatography as de-
scribed [33,34]. The beads were washed three times in bu¡er A and
bound protein eluted with VS.IEF sample bu¡er, as indicated.
2.6. p38 MAPK immunocomplex kinase assays
Jurkat cells were treated with anti-Fas IgM for the times indicated
in the ¢gure legends, extracts prepared and immunocomplex kinase
assays performed using anti-p38 MAPK polyclonal antiserum and
GST-ATF2 (Santa Cruz) as substrate as described [24]. The activity
of the immune complex was assayed at 30‡C for 30 min in 20 Wl
of kinase bu¡er (50 mM MOPS-KOH, pH 7.4, 2.5 mM EGTA,
0.1 mM EDTA, 10 mM MgCl2, 5 mM p-nitrophenylphosphate,
7 mM 2-mercaptoethanol, 2 mM benzamidine, 1 mM PMSF,
0.2 mM Na3VO4), in the presence of 10 WM ATP and 10 WCi of
[Q-32P]ATP. Reactions were terminated with SDS-PAGE sample
bu¡er and substrates separated on SDS-PAGE followed by quanti¢-
cation by a phosphoimager.
3. Results and discussion
3.1. Protein synthesis inhibition is an early event during
Fas-induced apoptosis in Jurkat cells
We have used the anti-Fas IgM antiserum to study how
activation of the CD95 signalling pathway impinges upon
the translational machinery during the process of apoptosis.
As shown in Fig. 1A, protein synthesis in Jurkat cells, meas-
ured by incorporation of [35S]methionine into acid-insoluble
material, is sensitive to anti-Fas IgM or etoposide, both of
which induce cell death (Fig. 1B). With either treatment, the
rate of translation declined to about 35^40% of control rates
within 6 h (Fig. 1C) and polysomes were disaggregated (data
not shown). The e¡ect of anti-Fas IgM on protein synthesis
and cell death was prevented by pre-treatment of cells with the
general caspase inhibitor, zVAD.FMK, which also main-
tained polysome integrity in the presence of anti-Fas IgM
(data not shown). In contrast, in etoposide-treated cells, cell
death but not the inhibition of protein synthesis, was pre-
vented by zVAD.FMK (Fig. 1A^C).
We have also used the immunosuppressant, rapamycin,
which, in mammalian cells, partially inhibits cap-dependent
initiation [35,36] by stabilising the interaction between
eIF4E and 4E-BP1 and preventing the association of eIF4E
with eIF4G [30,32]. Rapamycin has been shown to antagonise
the increase in protein synthesis brought about by insulin and
prevent the translation of the class of mRNAs containing a
5P polypyrimidine tract [31]. In the yeast Saccharomyces cere-
visiae, rapamycin also inhibits the basal rate of protein syn-
thesis [37]. In Jurkat cells, rapamycin does not a¡ect early
rates of translation following mitogenic stimulation [34,38]
and had a less potent inhibitory e¡ect than anti-Fas IgM,
reducing protein synthesis by only 40% after 24 h. Under
these assay conditions, rapamycin did not alter the phosphor-
ylation of 4E-BP1 or the binding of 4E-BP1 to eIF4E at early
times of incubation (data not shown). To determine whether
the observed inhibition of translation was a general e¡ect or
was speci¢c to certain classes of mRNA, cells were pulse-la-
belled with [35S]methionine at 6 h following various treat-
ments (in the presence of 1 mM unlabelled methionine to
reduce pool e¡ects), extracts prepared and aliquots containing
equal amounts of [35S]methionine-labelled protein resolved by
SDS-PAGE. As shown in Fig. 1A, although anti-Fas IgM or
etoposide decreased the overall rate of translation, this ap-
pears to be a general a¡ect on total protein synthesis with
no gross qualitative changes in the translation of speci¢c pro-
teins observed (Fig. 1D). Under these assay conditions, rapa-
mycin alone had no detectable e¡ect on the synthesis of spe-
ci¢c proteins (lane 5) and pre-treatment of cells with
rapamycin prior to anti-Fas IgM did not further decrease
the rate of translation over that of anti-Fas IgM alone (Fig.
1C, lane 6 vs 2), alter the spectrum of proteins synthesised
(Fig. 1D, lane 6 vs 2) or in£uence anti-Fas IgM-induced cell
death (data not shown). Two-dimensional gel electrophoresis
would be needed to detect more subtle changes in the syn-
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thesis of speci¢c proteins. Recently, Zhou et al. have reported
a severe inhibition of translation by anti-Fas IgM in Jurkat
cells which was not reversed by zVAD.FMK [39]. The reasons
for these di¡erences are unclear but may re£ect the fact that
Zhou et al. starved their cells prior to activation and measured
translation rates with reduced levels of unlabelled methionine
in the medium. Recently, such a regime has been shown to
result in the rapid deactivation of p70S6K and dephosphoryla-
tion of 4E-BP-1, rendering the cells unresponsive to all ago-
nists [40].
3.2. Anti-Fas IgM induces the acute degradation of eIF4G
Previously, we have reported that serum-starvation of
BJAB cells induces apoptosis with concomitant cleavage of
initiation factor eIF4G [33]. It is now established that the
large polypeptide chain initiation factor eIF4G plays a crucial
role in translation initiation by acting as a bridge between
other components such as the mRNA cap-binding protein
eIF4E and the multi-subunit eIF3 complex, which allows
the mRNA molecule to associate with the 40S ribosomal sub-
unit (reviewed in [41,42]). The association of the N-terminal
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Fig. 1. Anti-Fas IgM or etoposide treatment of Jurkat cells causes a general inhibition of translation and decreased cell viability. A: Jurkat
cells (106 cells in 1 ml, in triplicate) were preincubated for 60 min in the absence (F8RS) or presence (WP) of 50 WM zVAD.FMK prior to
a further incubation in the absence (F) or presence of 250 ng/ml anti-Fas IgM (RW), 100 Wg/ml etoposide (SP) or 10 nM rapamycin (8).
The rate of protein synthesis was estimated by pulse-labelling cells for 30 min with 10 WCi [35S]methionine before harvesting at the times indi-
cated. B: Parallel cultures of Jurkat cells were used to determine cell viability, as estimated by trypan blue exclusion. C: Jurkat cells (106 cells
in 1 ml, in triplicate) were preincubated for 60 min in the absence or presence of 50 WM zVAD.FMK, or 10 nM rapamycin, prior to a further
incubation for 6 h with vehicle alone, 250 ng/ml anti-Fas IgM, or 100 Wg/ml etoposide. The rate of translation was measured as in A, except
that pulse-labelling was for 15 min. Rates of protein synthesis are expressed as % of that obtained with vehicle alone. D: Parallel cultures of
cells (107 cells in 10 ml) as in C were used to prepare cell extracts, as described in Section 2. Aliquots containing equal cpm of radioactivity
were resolved by SDS-PAGE and the resulting autoradiograph is presented.
S.J. Morley et al./FEBS Letters 438 (1998) 41^48 43
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portion of eIF4G with eIF4E strongly enhances the binding of
the latter to 5P mRNA cap structures [43]. eIF4G possesses
domains for the binding of eIF3 in the central part of its
sequence, and also has binding sites for eIF4A [44^46] and
(at least in yeast) for the poly(A) binding protein (PABP) [47].
Interaction of PABP with eIF4G may allow functional asso-
ciation of the 3P end of an mRNA with the 5P end, thus
e¡ectively causing ‘circularisation’ of the mRNA during pro-
tein synthesis [48]. In this present study, we have investigated
the extent to which the decrease in translational activity in
Jurkat cells is associated with the loss of the key initiation
factor, eIF4G. Cells were incubated in the absence or presence
of zVAD.FMK before exposure to anti-Fas IgM for the times
indicated. Fig. 2 shows that within 2 h of treatment with anti-
Fas IgM there is a rapid degradation of eIF4G into its char-
acteristic cleavage products (p150, p76) and the appearance of
a speci¢c 89 kDa cleavage product of PARP [1,2]. At early
times of incubation with anti-Fas IgM, the integrity of eIF4E,
eIF2K, eIF4A, PABP and eIF4B were una¡ected (data not
shown). As with the e¡ects on translation, apoptosis-induced
cleavage of eIF4G and PARP was prevented by preincubating
the cells with zVAD.FMK (Fig. 2, lanes 13 vs 8), suggesting
that these proteins are targeted during programmed cell death.
In addition, extracts prepared from cells incubated with anti-
Fas IgM retained the ability to cleave exogenously added
eIF4F into the characteristic products, a process also pre-
vented by zVAD.FMK (S.J. Morley and L. McKendrick, un-
published data). As seen with anti-Fas IgM, etoposide also
promoted the cleavage of eIF4G and PARP (Fig. 2, lane 17
vs 16), and this was again prevented by zVAD.FMK (data not
shown). In all instances, the cleavage of eIF4G was una¡ected
by the calpain inhibitor, calpeptin, but accelerated by proteo-
some inhibitors such as MG132 (data not shown), consistent
with the ability of this compound to induce apoptosis in its
own right [59].
In an e¡ort to gain insight into which caspase(s) are im-
portant in the cleavage of eIF4G, we have extended these
studies to include the caspase 3-speci¢c cell permeable inhib-
itor, zDEVD.FMK. Fig. 3A shows that like zVAD.FMK
(lanes 4 vs 3), zDEVD.FMK (lanes 5 vs 3) also prevented
the anti-Fas IgM-induced cleavage of eIF4G observed at 4 h
following stimulation, and prevented cell death (Fig. 3B). The
fact that several disparate inducers of apoptosis, mediated by
the activation of one or more ‘executioner’ caspases and pos-
sibly via di¡erent mechanisms (reviewed in [1,2]), all lead to
the cleavage of eIF4G indicates that the pathways activated
by these agents converge on eIF4G. This is consistent with the
ability of the caspase inhibitors (zVAD.FMK and
zDEVD.FMK) to block the disappearance of eIF4G regard-
less of the apoptosis-inducing stimulus. However, etoposide
must a¡ect other processes in Jurkat cells as these caspase
inhibitors do not reverse the inhibition of translation observed
in these cells. It is noted that these data do not establish that
caspase 3 is the physiological catalyst of eIF4G cleavage, but
indicate that this caspase activity is necessary for the cleavage
of eIF4G. In addition, studies in vitro with recombinant cas-
pase 3 and in vivo with MCF-7 cells which naturally lack
caspase 3 activity have indicated that it is both necessary
and su⁄cient to cleave eIF4G (M. Bushell, L. McKendrick,
R. Janicke, and S.J. Morley, manuscript in preparation). At
this time, we do not know whether cleavage of eIF4G is the
cause or consequence of the inhibition of protein synthesis
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Fig. 3. Cleavage of eIF4G is prevented by zDEVD.FMK but is not a¡ected by SB203580. A: Jurkat cells (107 cells in 10 ml) were preincu-
bated for 60 min in the absence or presence of 50 WM zVAD.FMK, 50 WM zDEVD.FMK, 10 nM rapamycin or 50 WM SB203580 before fur-
ther incubation for 4 h with or without 250 ng/ml anti-Fas IgM, as indicated. Cell extracts were prepared and eIF4G was visualised as in Fig.
2. Results are representative of six experiments. B: Parallel cultures of Jurkat cells were used to determine cell viability, as estimated by trypan
blue exclusion. Vehicle alone (a) ; zVAD.FMK or SB203580 alone (W) ; anti-Fas IgM (R) ; anti-Fas IgM with zDEVD.FMK (S) ; rapamycin
(8) ; anti-Fas IgM with SB203580 (O).
Fig. 2. Inhibition of translation following the induction of apoptosis is correlated with the rapid cleavage of eIF4G and PARP. Jurkat cells
(2 ml) were preincubated for 60 min in the absence or presence of 50 WM zVAD.FMK before the addition of 250 ng/ml anti-Fas IgM, 100 Wg/
ml etoposide or 10 nM rapamycin (rapa), as indicated. At the times shown, cells were harvested, extracts prepared and equal amounts of pro-
tein (7.5 Wg) were resolved by SDS-PAGE. eIF4G and PARP were visualised by immunoblotting and the migration of the p150 and p76 cleav-
age products of eIF4G, and that of the 89 kDa cleavage product of PARP, are indicated. Results are representative of at least 10 experiments.
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reported here. Preliminary work has suggested that caspase
3-induced cleavage of eIF4G results in the inhibition of trans-
lation in the reticulocyte lysate (S.J. Morley and W. Wood,
unpublished data). Further work will be required to determine
the sites of cleavage of eIF4G in vivo and how the p76 frag-
ment in£uences translation of mRNA.
3.3. Rapamycin does not induce the cleavage of eIF4G in
Jurkat cells
In S. cerevisiae, nutrient deprivation or interruption of a
rapamycin-sensitive signalling pathway induces the cleavage
of eIF4G [49] and inhibition of translation initiation [37].
We therefore examined the e¡ect of rapamycin on the integ-
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Fig. 4. Arsenite, but not anti-Fas IgM, enhances the phosphorylation of eIF4E in Jurkat cells. A: Jurkat cells (107 cells in 10 ml) were incu-
bated with 250 ng/ml anti-Fas IgM for the times indicated, cell extracts prepared and equal amounts of protein (7.5 Wg) resolved by SDS-
PAGE. p38 and p38 phosphorylated on threonine 180/tyrosine 182 (P-38) were visualised by immunoblotting. B: Jurkat cells (107 cells in
10 ml) were incubated with 250 ng/ml anti-Fas IgM for 4 h, extracts prepared and aliquots containing equal amounts of protein (30 Wg) were
used to measure p38 MAPK activity in an immunocomplex kinase assay with GST-ATF2 as substrate, as described in Section 2. Presented
data are the means and S.D. (bars) of three separate experiments whilst the autoradiograph is from one such experiment. C: Jurkat cells
(107 cells in 10 ml) were incubated with 5 mM arsenite for the times indicated and the activation of p38 MAPK monitored as in A. D: Jurkat
cells (107 cells in 10 ml) were incubated with or without 50 WM SB203580 before incubation with 250 ng/ml anti-Fas IgM or 5 mM arsenite
for the times indicated. Cell extracts were prepared and eIF4E was isolated and analysed by VS.IEF and immunoblotting, as described in Sec-
tion 2. Results are representative of ¢ve experiments. E: Jurkat cells (107 cells in 10 ml) were incubated for 60 min with or without 50 WM
zVAD.FMK or SB203580, prior to the addition of vehicle alone (unstimulated), 250 ng/ml anti-Fas IgM or 10 Wg/ml etoposide for the times
indicated. The phosphorylation of eIF4E was analysed as in C. Results are representative of three experiments.
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rity of eIF4G in Jurkat cells. As shown in Fig. 2 (lanes 18 and
19) and Fig. 3 (lanes 6 vs 1), incubation with rapamycin alone
for 8 h or 4 h, respectively, did not induce the degradation of
eIF4G. In addition, rapamycin had no e¡ect of the ability of
anti-Fas IgM to inhibit translation rates (Fig. 1C), to induce
the cleavage of eIF4G (Fig. 3, lane 7) or in£uence cell death
(data not shown). This is in contrast to a ¢nding that rapa-
mycin can potentiate dexamethasone-induced apoptosis in S49
cells [50].
3.4. Cleavage of eIF4G does not require signalling through p38
MAPK
A variety of extracellular stimuli produce cellular responses
via activation of MAPKs (reviewed in [21,22,51]). The p38
subfamily of MAPKs consists of p38K, p38L, p38Q and
p38N, and regulates gene expression in response to stimuli
such as TNFK and interleukin-1 [51]. p38 is activated by
dual phosphorylation on threonine and tyrosine and in turn,
stimulates the activity of downstream transcription factors
and other protein kinases, such as MAPKAPK2, MAP-
KAPK3 and Mnk1 [51^54]. The latter has been identi¢ed as
a potential physiological kinase for translation initiation fac-
tor, eIF4E [53,54]. The p38 MAPK pathway has been impli-
cated as playing a critical role in apoptosis in several types of
cells [23,24,26], with the forced over-expression of p38K com-
petent to induce apoptosis, whilst that of p38L inhibits apop-
tosis in Jurkat cells [24]. Studies with various Jurkat cell
clones have shown that anti-Fas IgM induces the activation
of endogenous p38 MAPK, which correlates well with the
induction of apoptosis [26]. In order to address whether p38
MAPK activity was required for cleavage of eIF4G, we have
used SB203580, which inhibits the K and L forms of p38
MAPK [51]. Incubation of cells with SB203580 alone did
not induce the cleavage of eIF4G (Fig. 3A, lane 8) or promote
cell death to any degree (Fig. 3B). In contrast to caspase
inhibitors, pre-incubation of cells with SB203580 before expo-
sure to anti-Fas IgM (or etoposide; data not shown) did not
prevent apoptosis-induced eIF4G cleavage (Fig. 3A, lane 9)
and actually slightly potentiated cell death (Fig. 3B). Under
these assay conditions, inhibition of ERK MAPK by
PD98059 did not result in cell death or prevent the anti-Fas
IgM-induced cleavage of eIF4G (data not shown). Therefore,
these data show that signalling through p38 MAPK is not
required for anti-Fas IgM-induced apoptosis or the cleavage
of eIF4G.
3.5. Anti-Fas IgM activates p38 MAPK but does not increase
the phosphorylation of eIF4E
Initiation factor eIF4E plays a key role in mRNA trans-
lation and the regulation of this process by growth factors and
hormones. It is a phosphoprotein, with its phosphorylation
generally enhanced by agents which activate translation and
decreased in response to treatments which inhibit translation
(reviewed in [30,32]). However, it is still not clear how phos-
phorylation of eIF4E modulates its activity. Whilst there may
be a direct e¡ect of phosphorylation on cap structure recog-
nition in vitro [55], phosphorylation of eIF4E in vivo can also
be correlated with its enhanced interaction with eIF4G
[30,38,56,57]. Both e¡ects may be important in the activation
of protein synthesis under conditions that enhance eIF4E
phosphorylation. Studies from this lab [34,58] and others
[54] have shown that phorbol esters and cellular stress can
increase the phosphorylation of eIF4E. In Jurkat cells this
can occur via the p38 MAPK signalling pathway [34], possibly
mediated by activation of Mnk1 [53].
Consistent with published data [26], Fig. 4A shows that
anti-Fas IgM treatment of cells causes a modest increase the
phosphorylation (and hence activity) of p38 MAPK within
2 h, peaking at 4 h after addition. Immunoprecipitation and
in vitro kinase assays using GST-ATF2 as substrate showed
that although the twofold increase in the activity of p38
MAPK was dependent on caspase activity and was sensitive
to SB203580 (Fig. 4B), anti-Fas IgM treatment did not in-
crease the phosphorylation of eIF4E (Fig. 4D). Under the
same assay conditions, arsenite caused a more pronounced
activation of p38 MAPK (¢vefold, peaking at 30^60 min;
Fig. 4C) and increased the level of eIF4E phosphorylation
within 15 min of addition (Fig. 4D). Consistent with signalling
through the p38 MAPK pathway, the e¡ects of arsenite on
eIF4E phosphorylation were sensitive to SB203580 (Fig. 4D),
but insensitive to zVAD.FMK (data not shown). Fig. 4E
shows the e¡ect of anti-Fas IgM and etoposide on the phos-
phorylation of eIF4E over an extended time course. Although
anti-Fas IgM increased p38 MAPK activity, it did not in-
crease eIF4E phosphorylation above control levels. Etoposide
however, increased the phosphorylation of eIF4E within 2 h
(peaking at 4 h). Moreover, this increase was insensitive to
zVAD.FMK but sensitive to SB203580, consistent with a
model whereby etoposide activates multiple pathways in-
volved in activation of p38 MAPK and cell death [26].
The reasons why anti-Fas IgM does not increase the phos-
phorylation of eIF4E, in spite of the activation of p38 MAPK
and MAPKAPK2 (data not shown) are unclear. Previous
studies with this cell line have shown that phosphorylation
of eIF4E is modulated primarily at the level of protein phos-
phatase activity, with little evidence for changes in eIF4E
kinase activity [34]. Recently, Santoro et al. have shown
that phosphatase 2A activity is increased by 4.5-fold at 6 h
in anti-Fas IgM-treated Jurkat cells [59]. The importance of
this response in the modulation of eIF4E phosphorylation is
currently under investigation.
In conclusion, these data show that the anti-Fas IgM-in-
duced inhibition of protein synthesis in Jurkat cells is tempo-
rally correlated with the degradation of eIF4G. It is possible
that, in conjunction with the cleavage of eIF4G, maintenance
of eIF4E in the less phosphorylated form potentiates the in-
hibition of translation required for the progression of apop-
tosis in response to activation of the Fas receptor.
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